



Certificate of Analysis

FULL QUALITY CONTROL PANEL · PEPTIDE ANALYTICAL REPORT

CERTIFICATE NO.

COA-2026-9422

Issued 07/02/2026 · Page 1 of 4

CLIENT

PREPARED FOR

Aion Limitless

aionlimitless.com

Client reference: on file

Distribution: client confidential

SAMPLE & ACCESSION

ACC - 2026 - 7422

ANALYTE / IDENTITY

Tirzepatide

LABELED CONTENT

20 mg

MANUFACTURED

05/02/2026

DATE RECEIVED

06/28/2026

CAS NUMBER

2023788-19-2

SAMPLE MATRIX

Lyophilized

RETEST / EXPIRY

05/2028

DATE ANALYZED

07/02/2026

LOT NUMBER

TZ-2605

APPEARANCE

Conforms

STORAGE

-20 C, dark

DISPOSITION

RELEASED

PEPTIDE PURITY 99.20% Spec ≥ 95.0% ✓ PASS	IDENTITY Tirzepatide HPLC-RTM + LC-MS ✓ PASS	NET PEPTIDE CONTENT 20.10 mg measured · label 20 mg REPORTED	BACTERIAL ENDOTOXIN < 0.5 EU/vial · limit NMT 5 EU/mL ✓ PASS	DISPOSITION RELEASED Full QC Panel complete
--	---	---	--	---

1 RELEASE STATEMENT

Authorized Disposition

The submitted Tirzepatide sample was evaluated under the Full Quality Control Panel covering identity, purity, net peptide content, composition, sterility, bacterial endotoxin, elemental impurities, and targeted adulterant screening. Identity was confirmed by HPLC retention-time matching with an LC-MS deconvoluted neutral mass of 4813.5 Da. Chromatographic purity of 99.20 percent comfortably exceeded the not less than 95.0 percent release criterion. Sterility returned No Growth, bacterial endotoxin was well within the applicable limit, and arsenic, cadmium, chromium, mercury, and lead were each Not Detected, with fentanyl Not Detected at the screening cutoff. On the basis that all tested attributes meet their respective specifications, the laboratory supports a disposition of RELEASED for the material as received.


IDENTITY Confirmed ✓ PASS	PURITY 99.20% ✓ PASS	NET CONTENT 20.10 mg ✓ PASS	MOISTURE 3.80% w/w ✓ PASS	STERILITY No Growth ✓ PASS	ENDOTOXIN < 0.5 EU/vial ✓ PASS	HEAVY METALS Not Detected ✓ PASS
---	--	---	---	--	---	--

2 PURITY, QUANTITATION & IDENTITY

HPLC / HPLC-RTM

ANALYTE	SPECIFICATION	RESULT	UNIT	STATUS
Peptide Purity (HPLC)	≥ 95.0%	99.20	%	✓ PASS
Net Peptide Content	Report only	20.10	mg	REPORTED
Identity (HPLC-RTM)	Tirzepatide	Confirmed	—	✓ PASS
Fentanyl Screen	Immunoassay, 50 ng/mL	Not Detected	—	✓ PASS

Interpretation. The measured chromatographic purity of 99.20 percent exceeds the not less than 95.0 percent release criterion, indicating a homogeneous principal peak with a low related-substance burden. Net peptide content of 20.10 mg is the measured mass recovered from the unit and is reported against a nominal 20 mg label claim, confirming the vial delivers at least the labeled mass of active peptide.



3 REPRESENTATIVE CHROMATOGRAM

Reversed-phase HPLC-UV




Figure 2. Representative reversed-phase HPLC-UV chromatogram (Conformity unit V1, 99.14% main-peak area, near the batch mean of 99.15%). Trace related substances are shown magnified 10x in the inset. A sharp, symmetric principal peak with a low related-substance burden is consistent with high chromatographic purity.

PEAK	RT (MIN)	AREA (MAU·S)	AREA %	PLATES (N)	TAILING
Tirzepatide (principal)	8.90	4,957,000	99.14	8,420	1.06
Related substance 1 (RRT 0.88)	7.85	20,000	0.40	6,910	1.12
Related substance 2 (RRT 1.17)	10.40	14,000	0.28	6,540	1.10
Related substance 3 (RRT 1.37)	12.20	9,000	0.18	6,120	1.14
Total		5,000,000	100.00		

4 MASS CONFIRMATION

LC-MS, ESI positive



Figure 3. LC-MS mass confirmation (electrospray positive mode). The multiply-charged ion envelope from [M+3H]3+ to [M+6H]6+ deconvolutes to a neutral mass of 4813.5 Da, matching the theoretical mass of Tirzepatide and confirming identity.

5 CONFORMITY TESTING

3 units · HPLC

SAMPLE	PURITY	NPC (MG)	IDENTITY	RESULT
V0 (dedicated)	99.20%	20.10	Confirmed	✓ PASS
V1	99.14%	20.04	Confirmed	✓ PASS
V2	99.11%	20.22	Confirmed	✓ PASS
Mean	99.15%	20.12	—	—
Std Dev	0.046%	0.0917	—	—

Interpretation. Across three independently tested units the purity standard deviation was 0.046 percent and content standard deviation 0.0917 mg, a low dispersion consistent with a homogeneous, well-controlled batch.





Figure 4. Purity conformity across tested units with mean and plus or minus 3 SD control band (SD 0.046%).

6 COMPOSITION, MOISTURE & COUNTERION

KF · IC · USP <467>

PARAMETER	METHOD	SPECIFICATION	RESULT	STATUS
Net Peptide Content	HPLC / AAA	Report only	20.10 mg	REPORTED
Water (Karl Fischer)	USP <921>	NMT 8.0% w/w	3.80%	✓ PASS
Counterion (acetate)	Ion chromatography	Report only	7.90% w/w	REPORTED
Residual Solvents (TFA)	USP <467>	Not Detected	Not Detected	✓ PASS
Gross Fill Weight	Gravimetric	Report only	23.38 mg	REPORTED

Interpretation. Karl Fischer titration returned 3.80 percent residual water and the acetate counterion accounts for 7.90 percent by weight, both typical for a freeze-dried peptide salt. The 23.38 mg gross fill reconciles peptide, counterion, water, and trace related substances.




7 SAFETY & CONTAMINATION CONTROLS

ICP-MS · USP <71> · <85>

TEST	METHOD	SPECIFICATION	RESULT	STATUS
Arsenic (As)	ICP-MS	NMT 1.5 ppm	Not Detected	✓ PASS
Cadmium (Cd)	ICP-MS	NMT 0.5 ppm	Not Detected	✓ PASS
Chromium (Cr)	ICP-MS	NMT 10 ppm	Not Detected	✓ PASS
Mercury (Hg)	ICP-MS	NMT 1.5 ppm	Not Detected	✓ PASS
Lead (Pb)	ICP-MS	NMT 1 ppm	Not Detected	✓ PASS
Sterility	USP <71>	No Growth	No Growth	✓ PASS
Bioburden	USP <61>	< 10 CFU/mL	< 1 CFU/mL	✓ PASS
Bacterial Endotoxin	USP <85>	NMT 5 EU/mL	< 0.5 EU/vial	✓ PASS

Interpretation. By ICP-MS, arsenic, cadmium, chromium, mercury, and lead were each Not Detected below their specification thresholds. Sterility by membrane filtration returned No Growth with bioburden below the reporting limit, and bacterial endotoxin measured < 0.5 EU/vial, at or below 0.50 EU/mL once reconstituted in 1 mL or more, within the not more than 5 EU/mL release limit.



8 FOR THE RECIPIENT

Plain-language summary

- ✓ **Purity 99.20 percent.** Almost everything in the vial is Tirzepatide. Only 0.80 percent is trace related substances, comfortably past the 95 percent release bar.
- ✓ **You get at least the labeled amount.** Measured net peptide content is 20.10 mg, at or above the 20 mg on the label, so the measured content meets or exceeds the label claim.
- ✓ **It is genuinely Tirzepatide.** HPLC retention time plus an LC-MS deconvoluted neutral mass of 4813.5 Da confirm the identity, so this is not a substitute or a mislabel.
- ✓ **Sterility and endotoxin within specification.** Sterility shows No Growth, and bacterial endotoxin measured < 0.5 EU/vial, which stays under the not more than 5 EU/mL limit at the tested reconstitution volume.
- ✓ **Screened for contamination.** Arsenic, cadmium, chromium, mercury, and lead were Not Detected, and the fentanyl adulterant screen was Not Detected.
- ✓ **Water and salt are normal.** The small amounts of water (3.80 percent) and acetate (7.90 percent) are expected for a freeze-dried peptide and are already accounted for in the net peptide figure.

Purity (HPLC)

Percent of the main peptide peak relative to all detected peaks.

Net peptide content

Measured mass of actual peptide, separate from water and salt.

NMT

Not more than; an upper acceptance limit.

Not Detected

Below the method limit of quantitation (LOQ).

EU/mL

Endotoxin units per milliliter, a measure of bacterial toxin.

RRT

Relative retention time; an impurity position versus the main peak.

Counterion

The salt partner of the peptide.

w/w

By weight, as a percent of total mass.

USP <71> / <85>

Standard chapters for sterility and bacterial endotoxin.

Karl Fischer

Titration method for measuring residual water (USP <921>).

Storage. Store the sealed lyophilized vial at -20 C, protected from light. Reconstituted solution is stable at 2 to 8 C; use within 30 days. **Reconstitution.** Add bacteriostatic or sterile water down the vial wall, swirl gently, do not shake. **Handling.** Research use only; not for human or veterinary use.

9 ANALYTICAL METHODS & NOTES

Method principles

HPLC Purity and Net Peptide Content

Reversed-phase HPLC with UV detection separates the principal peptide from related substances; purity is percent main-peak area and content is quantified against a calibrated reference. Acceptance: not less than the stated release limit.

LC-MS Mass Confirmation

Electrospray positive-mode mass spectrometry resolves the molecular ion and isotope or charge-state signature of the analyte.

Counterion by Ion Chromatography

Ion chromatography determines the counterion content by weight, characterizing the peptide salt form.

Heavy Metals by ICP-MS

Inductively coupled plasma mass spectrometry quantifies elemental impurities against per-element limits, with results below detection reported as Not Detected.

Bioburden by USP <61>

Total aerobic microbial and yeast or mold counts establish microbial load prior to release.

Identity by HPLC Retention-Time Matching

Sample retention time is compared to a qualified reference standard under identical conditions; identity is confirmed on co-elution within the established window.

Water Content by Karl Fischer

Coulometric Karl Fischer titration per USP <921> quantifies residual moisture in the lyophilized cake. Acceptance: not more than 8.0 percent w/w.

Residual Solvents

Headspace GC per USP <467> screens process solvents; trifluoroacetic acid is assessed against a not-detected threshold.

Sterility by USP <71>

Membrane filtration sterility test; No Growth is reported when no microbial recovery is observed across the incubation period.

Bacterial Endotoxin by USP <85>

Kinetic bacterial endotoxin test; acceptance is not more than 5 EU/mL per client specification.

DocuSigned by:



11011100 11001011 11110110 00111101

DS

FC

Finn C.

Laboratory Director

Date of authorization: 07/02/2026

DocuSigned by:



00101010 01001010 10000000 10101011

DS

BC

Brennan C.

Quality Assurance

Reviewed against acceptance criteria: 07/02/2026



Authenticate this certificate

Scan the code or verify online at titreonanalytical.com/verify/COA-2026-9422

Verification ID: TLA-9422-TIRZ-B7E2



Scope and disclaimer. These results relate only to the item tested as received and do not extend to any other unit, lot, or batch; this certificate shall not be reproduced except in full without the prior written approval of the laboratory. The graphical exhibits shown, including the chromatogram, mass spectrum, composition, conformity, headroom, mass-balance, and margin panels, are rendered representations generated from the reported analytical results for illustrative clarity, with primary instrument data files retained on record. Information herein is confidential to the named client, and liability is limited to the value of the analytical service performed. Research use only; not for human or veterinary use. Titreon is an independent analytical laboratory and does not manufacture, sell, or endorse any product it tests.